Wound care company Odinwell reports unchanged revenue in the first quarter while earnings fell slightly. Revenue amounted to SEK 1.1 million (1.1). Operating profit improved to SEK -1.2 million (-1.8), while net profit amounted to SEK -1.2 million (-1.7). Earnings per share improved to SEK -0.02 (-0.07). Cash and cash equivalents were SEK 2.8 million (1.5).During the quarter, the company launched an innovation project together with a strategic customer and also announced ongoing projects with several veterinary clinics to develop a veterinary medicine version of the company's wound care technology. CEO Marcus Andersson states that the company is now formally entering veterinary medicine as the first market for the novaQS technology. The company is collaborating with two veterinary clinics where data is being collected from wounds on horses and has also initiated production of a smaller series of novaQS for selected customers in veterinary and human medicine. The goal is to have production of a veterinary medicine product operational during the second half of 2026. Odinwell, SEK millionQ1 2026Q1 2025Revenue1.11.1Operating profit-1.2-1.8Net profit-1.2-1.7Earnings per share, kronor-0.02-0.07